Adaptive Biotechnologies Corporation (ADPT)
Health Care ยท Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corporation (ADPT) is listed on Nasdaq, where its shares have traded since June 27, 2019. SentiSense covers Adaptive Biotechnologies Corporation in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Chad Robins is its chief executive officer. The company reports 624 employees, and its corporate website is www.adaptivebiotech.com.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Institutional ownership
In 13F filings for the quarter ended September 30, 2026, 242 institutions reported holding ADPT, with 86.2 million shares worth $2.5 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Geode Capital Management. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on ADPT
- ADPT sentiment: whether news and social coverage of Adaptive Biotechnologies Corporation leans bullish or bearish, and the stories driving it.
- ADPT ownership: all 242 reporting institutions, plus insider and congressional trades.
- ADPT financials: revenue, net income, operating margin and free cash flow by quarter and year.
Frequently asked questions
What does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
What sector is ADPT in?
SentiSense classifies Adaptive Biotechnologies Corporation in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does ADPT stock trade?
Adaptive Biotechnologies Corporation (ADPT) is listed on Nasdaq, where its shares have traded since June 27, 2019.
Who is the CEO of Adaptive Biotechnologies Corporation?
Chad Robins is the chief executive officer of Adaptive Biotechnologies Corporation.